Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
attenuated MVA monkeypox vaccine
- Development stage
- Unknown
- Lead developer
- Shanghai Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The attenuated MVA monkeypox vaccine is a live-attenuated viral vaccine based on the Modified Vaccinia Ankara (MVA) strain, developed by the Shanghai Institute of Biological Products (SIBP), a subsidiary of Sinopharm (China National Biotec Group). MVA is a highly attenuated, non-replicating or poorly replicating orthopoxvirus that has been extensively used as a safe vaccine vector. This specific candidate is designed to prevent monkeypox (mpox) infection by inducing active immunity against the monkeypox virus. In clinical evaluation, it is administered via a two-dose subcutaneous schedule, with doses given 28 days apart. The vaccine is currently undergoing Phase I clinical trials in China to assess its safety and immunogenicity in adults.
- Other names
- MVA monkeypox attenuated live vaccineModified Vaccinia Ankara monkeypox vaccine减毒猴痘疫苗（MVA株）
02
Targets
OPXV MV/EEV antigens (Orthopoxvirus mature virion and extracellular enveloped virion surface antigens)
Beyond the preview
Go deeper on attenuated MVA monkeypox vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on attenuated MVA monkeypox vaccine.